Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.
Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...
The Investment Committee give you their top stocks to watch for the second half.
This was the stock's fourth consecutive day of gains.
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...
Zacks.com on MSN1d
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key MetricsThe upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback